GLP-1 receptor agonist medications like Ozempic, Mounjaro, and Wegovy are now widely available through Australian weight loss clinics and telehealth providers, but costs vary enormously — from around $130 to over $650 per month depending on the drug, dose, and whether you qualify for PBS subsidy. This 2026 guide breaks down every cost, eligibility rule, and practical consideration so you can make an informed decision before booking your first appointment.
What are GLP-1 medications and why is everyone talking about them?
GLP-1 (glucagon-like peptide-1) receptor agonists are a class of injectable medications originally developed to manage type 2 diabetes that have since become the most talked-about weight loss tools in modern medicine. They work by mimicking a naturally occurring gut hormone that signals fullness, slows gastric emptying, and reduces appetite — often dramatically.
In Australia, the three names you'll hear most often are Ozempic (semaglutide, approved for type 2 diabetes), Wegovy (higher-dose semaglutide, approved for chronic weight management), and Mounjaro (tirzepatide, approved for type 2 diabetes and, as of late 2025, weight management under the brand name Zepbound). A fourth option, Saxenda (liraglutide), remains available but is less frequently prescribed given that newer agents generally produce superior results.
Clinical trials published in the *New England Journal of Medicine* found that weekly semaglutide (Wegovy-dose) produced an average body weight reduction of around 15%, while tirzepatide trials recorded reductions of up to 22.5% in some cohorts — figures that have fundamentally shifted how clinicians approach obesity treatment.
PBS eligibility: who pays less, and who pays full price?
The Pharmaceutical Benefits Scheme (PBS) is the single biggest factor in how much Australians pay for GLP-1 therapy. Understanding eligibility upfront will save you a great deal of confusion at the pharmacy counter.
Ozempic is PBS-listed for adults with type 2 diabetes who meet specific HbA1c and treatment history criteria. In 2026, the PBS co-payment for general patients is approximately $31.60 per script, and concession cardholders pay around $7.70. If your doctor prescribes Ozempic *off-label* for weight loss alone — meaning you do not have a diabetes diagnosis — you will pay the full private price, typically $130–$160 per pen (one month's supply at lower doses). Wegovy received TGA approval in Australia in 2023 but, as at the time of writing in 2026, remains not PBS-listed for weight management. This means almost all Australians using it for weight loss pay the full private price of approximately $395–$450 per month. Mounjaro / Zepbound (tirzepatide) is PBS-listed for type 2 diabetes but the Zepbound weight-management indication is not yet subsidised, making private costs approximately $480–$650 per month at higher doses.According to the Australian Bureau of Statistics (ABS) 2022–23 National Health Survey, approximately 66% of Australian adults are living with overweight or obesity — a statistic that underscores both the enormous demand for these treatments and the pressure advocates are placing on the government to expand PBS access.
2026 GLP-1 medication cost comparison table
The following table reflects average 2026 Australian private market pricing sourced from major telehealth providers, compounding pharmacies, and retail chains. PBS prices apply only where the clinical indication is met.
| Medication | Active Ingredient | PBS Listed (Weight Loss)? | Private Monthly Cost (AUD) | PBS Monthly Cost (AUD) | |---|---|---|---|---| | Ozempic (0.5–1mg) | Semaglutide | No (diabetes only) | $130–$160 | ~$31.60 (diabetes Rx) | | Wegovy (0.25–2.4mg) | Semaglutide | No | $395–$450 | N/A | | Mounjaro / Zepbound (2.5–15mg) | Tirzepatide | No (diabetes only) | $480–$650 | ~$31.60 (diabetes Rx) | | Saxenda (up to 3mg daily) | Liraglutide | No | $280–$340 | N/A | | Compounded semaglutide | Semaglutide | No | $100–$200 | N/A |*Note: Compounded semaglutide is prepared by TGA-approved compounding pharmacies and is legal in Australia where a valid prescription exists, though it is not TGA-approved as a finished product. Always discuss risks with your prescribing doctor.*
For a full breakdown of clinic fees, consultation charges, and monitoring costs, see our cost guide.
Where to access GLP-1 prescriptions: clinics, GPs, and telehealth
Australians have three main pathways to a GLP-1 prescription in 2026.
Your regular GP remains the most affordable starting point. A standard consultation under a chronic disease management plan may be bulk-billed or attract a modest gap. However, some GPs are cautious about prescribing off-label for weight loss and may refer you to a specialist. Weight loss clinics — including dedicated obesity medicine practices and bariatric centres — offer structured programmes that typically include dietary coaching, psychological support, and medical oversight alongside the prescription. Costs are higher (initial consultations often $150–$400) but the comprehensive care model is associated with better long-term outcomes. If you're based in New South Wales, our roundup of best weight loss clinics in Sydney covers accredited providers with transparent pricing. Telehealth providers have proliferated rapidly since 2021 and several Australian platforms now specialise specifically in GLP-1 prescribing. Subscription models typically bundle the consultation, prescription, and sometimes the medication itself for a flat monthly fee ranging from $199 to $399. Convenience is high, but critics note that the depth of clinical assessment can vary. Always check that the prescriber is registered with AHPRA and that the platform has a structured follow-up protocol.Hidden costs Australians often overlook
The sticker price of the medication is rarely the full story. A realistic annual budget should account for:
- Pathology tests: Baseline bloods (HbA1c, lipid panel, liver function, kidney function) cost $0 if bulk-billed, but private pathology can run $80–$150 per set. You may need these every three to six months. - Consultation fees: Ongoing script renewals typically require a review every one to three months, at $40–$200 per appointment depending on provider type. - Needles and sharps disposal: A minor but recurring cost of approximately $10–$20 per month. - Anti-nausea medication: Commonly prescribed for the first few weeks; generally inexpensive under PBS.
A 2023 Productivity Commission report on health system sustainability noted that out-of-pocket health costs for Australians have grown at nearly twice the rate of the consumer price index over the preceding decade — making cost transparency in emerging treatment categories like GLP-1 therapy increasingly important for consumers.
What results can Australians realistically expect?
Efficacy data is genuinely impressive, but it comes with important nuance. Most clinical trials measure results under closely monitored conditions with structured lifestyle programmes running alongside medication. In real-world Australian clinical practice, results are meaningful but typically somewhat lower than headline trial figures.
Clinicians generally advise patients to expect 5–12% body weight reduction in the first six months on semaglutide, with continued loss through twelve months. Tirzepatide tends to produce faster and larger reductions for many patients. Critically, the evidence also shows that weight returns for most people if medication is stopped without long-term lifestyle change — making the ongoing cost commitment a central part of the decision.
Patients with type 2 diabetes often see additional benefits including improved glycaemic control and, in some studies, reduced cardiovascular risk. These broader health outcomes strengthen the case for expanded PBS access, which advocacy groups continue to pursue.
How to choose the right clinic or provider
Not all providers are equal. When evaluating a weight loss clinic or telehealth service for GLP-1 therapy, prioritise the following:
- AHPRA-registered prescribers with demonstrable experience in obesity medicine or endocrinology - Transparent, itemised pricing before you commit — ask specifically about consultation, pathology, and medication renewal costs - Structured follow-up protocols including regular check-ins and clear escalation pathways if side effects occur - Access to multidisciplinary support — dietitian, psychologist, and exercise physiologist involvement is associated with substantially better long-term weight maintenance - No lock-in contracts or penalties for pausing or stopping treatment
Our independent methodology explains in detail how we assess and rate Australian weight loss providers, including the specific criteria applied to GLP-1 prescribing services.
---
Frequently asked questions
Q: Can I get Ozempic for weight loss on the PBS in Australia? A: Not currently. As at 2026, Ozempic's PBS listing covers type 2 diabetes only. If you're using it solely for weight management without a diabetes diagnosis, you'll pay the full private price of roughly $130–$160 per pen. Wegovy (the weight-management-approved form of semaglutide) is TGA-approved but not PBS-subsidised for weight loss. Q: Is compounded semaglutide safe and legal in Australia? A: Compounded semaglutide can be legally prepared and prescribed in Australia when a licensed compounding pharmacy fills a valid doctor's prescription. It is not TGA-approved as a finished therapeutic good, which means quality and concentration consistency can vary between compounders. The TGA has issued guidance advising patients to use approved products where available, so discuss the risks and benefits thoroughly with your prescribing doctor. Q: How long will I need to stay on a GLP-1 medication? A: Current evidence suggests these medications work best as long-term treatments rather than short courses. Studies consistently show significant weight regain after stopping. Many Australian obesity physicians now frame GLP-1 therapy similarly to blood pressure medication — as an ongoing management tool — particularly for patients with obesity-related health complications. Q: Will private health insurance cover GLP-1 medications in Australia? A: In most cases, no. Australian private health insurance covers hospital and ancillary (extras) services, not outpatient PBS or private prescription costs. Some higher-tier extras policies may partially reimburse consultation fees with a dietitian or specialist, but the medication cost itself is generally an out-of-pocket expense. It's worth reviewing your policy's chronic disease management provisions and contacting your insurer directly.---
Browse our independent directory at /best/.